{"protocolSection": {"identificationModule": {"nctId": "NCT01006590", "orgStudyIdInfo": {"id": "D1680L00003"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes", "officialTitle": "A 24-Week, Randomised, Double-Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Add-On Compared to Uptitration of Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycaemic Control on Sub-Maximal Doses of Metformin", "acronym": "PROMPT"}, "statusModule": {"statusVerifiedDate": "2012-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-10"}, "completionDateStruct": {"date": "2010-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-10-31", "studyFirstSubmitQcDate": "2009-11-02", "studyFirstPostDateStruct": {"date": "2009-11-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-11-30", "resultsFirstSubmitQcDate": "2011-11-30", "resultsFirstPostDateStruct": {"date": "2012-01-05", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-01-16", "lastUpdatePostDateStruct": {"date": "2012-01-19", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}, "collaborators": [{"name": "Bristol-Myers Squibb", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The study will evaluate the efficacy and tolerability of saxagliptin compared to uptitration of metformin in patients with type 2 diabetes who have inadequate glycaemic control on a submaximal dose of metformin."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"], "keywords": ["Type 2 Diabetes Mellitus", "Saxagliptin", "Randomised", "Double-blind"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 286, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "Saxagliptin 5 mg", "interventionNames": ["Drug: Saxagliptin"]}, {"label": "2", "type": "ACTIVE_COMPARATOR", "description": "Metformin 500 -1000 mg", "interventionNames": ["Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Saxagliptin", "description": "5 mg, oral tablet, once daily", "armGroupLabels": ["1"], "otherNames": ["Onglyza"]}, {"type": "DRUG", "name": "Metformin", "description": "500 mg, oral tablet, 1 or 2 additional tablets per day added to background therapy", "armGroupLabels": ["2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Absolute Change From Baseline in HbA1c at Week 24", "timeFrame": "Baseline and 24 weeks"}], "secondaryOutcomes": [{"measure": "Proportion of Patients Achieving a Therapeutic Response at Week 24 Defined as HbA1c<7.0%", "description": "Proportion, percentage of patients in each treatment group, achieving therapeutic response, HbA1c below 7.0 percent", "timeFrame": "24 Weeks"}, {"measure": "Proportion of Patients Achieving a Therapeutic Response at Week 24 Defined as HbA1c<=6.5%", "description": "Proportion, percentage of patients in each treatment group, achieving therapeutic response, HbA1c below or equal to 6.5 percent", "timeFrame": "24 Weeks"}, {"measure": "Change From Baseline to Week 24 in Fasting Plasma Glucose", "timeFrame": "Baseline and 24 weeks"}, {"measure": "Change From Baseline to Week 24 in Fasting Insulin", "timeFrame": "Baseline and 24 weeks"}, {"measure": "Change From Baseline to Week 24 in Beta-cell Function as Measured by Homeostasis Model Assessment-2-beta", "timeFrame": "Baseline and 24 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Provision of signed informed consent\n* Established clinical diagnosis of type 2 diabetes. Treatment with a stable dose of metformin monotherapy (1500-1700 mg/day) for at least 8 weeks prior to visit 1.\n* HbA1c \u22657.0% and \u226410.0%\n\nExclusion Criteria:\n\n* Type 1 diabetes, history of diabetic ketoacidosis or hyperosmolar non-ketonic coma.\n* Renal impairment as defined by a creatinine clearance \\<60 mL/min/1.73 m2\n* Individuals who, in the opinion of the investigator, in which participation in this study may pose a significant risk to the patient and could render the patient unable to successfully complete the study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Research Site", "city": "Brugge", "country": "Belgium", "geoPoint": {"lat": 51.20892, "lon": 3.22424}}, {"facility": "Research Site", "city": "Brussels (woluwe-st-lambert)", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "Research Site", "city": "Halen", "country": "Belgium", "geoPoint": {"lat": 50.94837, "lon": 5.11096}}, {"facility": "Research Site", "city": "Lommel", "country": "Belgium", "geoPoint": {"lat": 51.23074, "lon": 5.31349}}, {"facility": "Research Site", "city": "Moerkerke", "country": "Belgium", "geoPoint": {"lat": 51.24547, "lon": 3.34251}}, {"facility": "Research Site", "city": "Oostham", "country": "Belgium", "geoPoint": {"lat": 51.10374, "lon": 5.17877}}, {"facility": "Research Site", "city": "Sint-gillis-waas", "country": "Belgium", "geoPoint": {"lat": 51.21914, "lon": 4.12374}}, {"facility": "Research Site", "city": "Tielt", "country": "Belgium", "geoPoint": {"lat": 50.99931, "lon": 3.32707}}, {"facility": "Research Site", "city": "Zoersel", "country": "Belgium", "geoPoint": {"lat": 51.26825, "lon": 4.71296}}, {"facility": "Research Site", "city": "Chatellerault", "country": "France", "geoPoint": {"lat": 46.8, "lon": 0.53333}}, {"facility": "Research Site", "city": "Corbeil Essonnes", "country": "France", "geoPoint": {"lat": 48.60603, "lon": 2.48757}}, {"facility": "Research Site", "city": "La Rochelle", "country": "France", "geoPoint": {"lat": 46.16667, "lon": -1.15}}, {"facility": "Research Site", "city": "La Seyne Sur Mer", "country": "France", "geoPoint": {"lat": 43.09818, "lon": 5.88471}}, {"facility": "Research Site", "city": "Paris", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Research Site", "city": "Seysses", "country": "France", "geoPoint": {"lat": 43.49801, "lon": 1.31081}}, {"facility": "Research Site", "city": "Tierce", "country": "France", "geoPoint": {"lat": 47.61587, "lon": -0.46609}}, {"facility": "Research Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Freiburg", "country": "Germany", "geoPoint": {"lat": 47.9959, "lon": 7.85222}}, {"facility": "Research Site", "city": "Leipzig", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Research Site", "city": "Ludwigshafen", "country": "Germany", "geoPoint": {"lat": 49.48121, "lon": 8.44641}}, {"facility": "Research Site", "city": "Mannheim", "country": "Germany", "geoPoint": {"lat": 49.4891, "lon": 8.46694}}, {"facility": "Research Site", "city": "Rhaunen", "country": "Germany", "geoPoint": {"lat": 49.86322, "lon": 7.34232}}, {"facility": "Research Site", "city": "Schmiedeberg", "country": "Germany", "geoPoint": {"lat": 50.83644, "lon": 13.67622}}, {"facility": "Research Site", "city": "Wahlstedt", "country": "Germany", "geoPoint": {"lat": 53.95161, "lon": 10.20626}}, {"facility": "Research Site", "city": "Bergamo", "state": "BG", "country": "Italy", "geoPoint": {"lat": 45.69601, "lon": 9.66721}}, {"facility": "Research Site", "city": "Forli", "state": "FC", "country": "Italy", "geoPoint": {"lat": 44.22177, "lon": 12.04144}}, {"facility": "Research Site", "city": "Milano", "state": "MI", "country": "Italy", "geoPoint": {"lat": 45.46427, "lon": 9.18951}}, {"facility": "Research Site", "city": "Padova", "state": "PD", "country": "Italy", "geoPoint": {"lat": 45.40797, "lon": 11.88586}}, {"facility": "Research Site", "city": "Pordenone", "state": "PN", "country": "Italy", "geoPoint": {"lat": 45.95689, "lon": 12.66051}}, {"facility": "Research Site", "city": "Siena", "state": "SI", "country": "Italy", "geoPoint": {"lat": 43.31822, "lon": 11.33064}}, {"facility": "Research Site", "city": "Roma", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}, {"facility": "Research Site", "city": "Sevilla", "state": "Andalucia", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "Research Site", "city": "Oviedo", "state": "Asturias", "country": "Spain", "geoPoint": {"lat": 43.36029, "lon": -5.84476}}, {"facility": "Research Site", "city": "Barcelona", "state": "Cataluna", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Research Site", "city": "Madrid", "state": "Comunidad de Madrid", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Research Site", "city": "San Sebastian de Los Reyes", "state": "Comunidad de Madrid", "country": "Spain", "geoPoint": {"lat": 40.55555, "lon": -3.62733}}, {"facility": "Research Site", "city": "Alicante", "state": "Comunidad Valenciana", "country": "Spain", "geoPoint": {"lat": 38.34517, "lon": -0.48149}}, {"facility": "Research Site", "city": "A Coruna", "state": "Galicia", "country": "Spain", "geoPoint": {"lat": 43.37135, "lon": -8.396}}, {"facility": "Research Site", "city": "Ankara", "country": "Turkey", "geoPoint": {"lat": 39.91987, "lon": 32.85427}}, {"facility": "Research Site", "city": "Bursa", "country": "Turkey", "geoPoint": {"lat": 40.19559, "lon": 29.06013}}, {"facility": "Research Site", "city": "Kirikkale", "country": "Turkey", "geoPoint": {"lat": 39.84528, "lon": 33.50639}}, {"facility": "Research Site", "city": "Reading", "state": "Berks", "country": "United Kingdom", "geoPoint": {"lat": 51.45625, "lon": -0.97113}}, {"facility": "Research Site", "city": "Atherstone", "state": "Warwickshire", "country": "United Kingdom", "geoPoint": {"lat": 52.57536, "lon": -1.54693}}, {"facility": "Research Site", "city": "Leamington Spa", "state": "Warwks", "country": "United Kingdom", "geoPoint": {"lat": 52.3, "lon": -1.53333}}, {"facility": "Research Site", "city": "Warminster", "state": "Wiltshire", "country": "United Kingdom", "geoPoint": {"lat": 51.20434, "lon": -2.17873}}, {"facility": "Research Site", "city": "Westbury", "state": "Wiltshire", "country": "United Kingdom", "geoPoint": {"lat": 51.26, "lon": -2.1875}}, {"facility": "Research Site", "city": "Ashford", "country": "United Kingdom", "geoPoint": {"lat": 51.14648, "lon": 0.87376}}, {"facility": "Research Site", "city": "Bath", "country": "United Kingdom", "geoPoint": {"lat": 51.3751, "lon": -2.36172}}, {"facility": "Research Site", "city": "Coventry", "country": "United Kingdom", "geoPoint": {"lat": 52.40656, "lon": -1.51217}}, {"facility": "Research Site", "city": "Peterborough", "country": "United Kingdom", "geoPoint": {"lat": 52.57364, "lon": -0.24777}}]}, "referencesModule": {"references": [{"pmid": "23020253", "type": "DERIVED", "citation": "Hermans MP, Delibasi T, Farmer I, Lohm L, Maheux P, Piatti P, Malvolti E, Jorgens S, Charbonnel B. Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study. Curr Med Res Opin. 2012 Oct;28(10):1635-45. doi: 10.1185/03007995.2012.735646. Epub 2012 Oct 12."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Screening, enrollment (2 weeks) and lead-in period (4 weeks). Main reason for not being randomised was due to renal function not meeting inclusion criteria. (Samples taken and analysed after enrollment into the study but prior to randomisation).", "recruitmentDetails": "The study was conducted at hospital clinics and general practitioners. Patient recruitment started October 20, 2009 and was completed April 30, 2010", "groups": [{"id": "FG000", "title": "Saxagliptin", "description": "Saxagliptin, 5 mg once daily add-on to Metformin 1500 mg/day"}, {"id": "FG001", "title": "Metformin Uptitration", "description": "Metformin uptitration, 500-1000 mg daily , add-on to Metformin 1500 mg/day"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Randomised and treated", "numSubjects": "147"}, {"groupId": "FG001", "comment": "Randomised and treated", "numSubjects": "139"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Completed 24 weeks of treatment", "numSubjects": "119"}, {"groupId": "FG001", "comment": "Completed 24 weeks of treatment", "numSubjects": "107"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "28"}, {"groupId": "FG001", "numSubjects": "32"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Study specific discontinuation criteria", "reasons": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "23"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Saxagliptin", "description": "Saxagliptin, 5 mg once daily add-on to Metformin 1500 mg/day"}, {"id": "BG001", "title": "Metformin Uptitration", "description": "Metformin uptitration, 500-1000 mg daily , add-on to Metformin 1500 mg/day"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "147"}, {"groupId": "BG001", "value": "139"}, {"groupId": "BG002", "value": "286"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58.7", "spread": "11.31"}, {"groupId": "BG001", "value": "58.6", "spread": "9.79"}, {"groupId": "BG002", "value": "58.7", "spread": "10.58"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "59"}, {"groupId": "BG001", "value": "63"}, {"groupId": "BG002", "value": "122"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "88"}, {"groupId": "BG001", "value": "76"}, {"groupId": "BG002", "value": "164"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Absolute Change From Baseline in HbA1c at Week 24", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-11", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent (%)", "timeFrame": "Baseline and 24 weeks", "groups": [{"id": "OG000", "title": "Saxagliptin", "description": "Saxagliptin, 5 mg once daily add-on to Metformin 1500 mg/day"}, {"id": "OG001", "title": "Metformin Uptitration", "description": "Metformin uptitration, 500-1000 mg daily , add-on to Metformin 1500 mg/day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "146"}, {"groupId": "OG001", "value": "137"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.47", "spread": "0.06"}, {"groupId": "OG001", "value": "-0.38", "spread": "0.06"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The null hypothesis H0: \u00b5t-\u00b5C=0, where \u03bcT denotes the mean absolute change in HbA1c from baseline to Week 24 in the group of patients treated with saxagliptin (test medication, T) and \u03bcC the mean absolute change in HbA1c from baseline to Week 24 in the group of patients with uptitration of metformin (comparator, C) A sample size of 120 randomized and treated patients per treatment group yielded 80% power under the assumption of a true treatment difference of 0.4% and a standard deviation of 1.1%", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.26", "statisticalMethod": "ANCOVA", "statisticalComment": "With baseline value as covariate and treatment group as factor; comparison of LSmeans for treatment", "paramType": "Mean Difference (Net)", "paramValue": "-0.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.26", "ciUpperLimit": "0.07", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.09"}]}, {"type": "SECONDARY", "title": "Proportion of Patients Achieving a Therapeutic Response at Week 24 Defined as HbA1c<7.0%", "description": "Proportion, percentage of patients in each treatment group, achieving therapeutic response, HbA1c below 7.0 percent", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-11", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "24 Weeks", "groups": [{"id": "OG000", "title": "Saxagliptin", "description": "Saxagliptin, 5 mg once daily add-on to Metformin 1500 mg/day"}, {"id": "OG001", "title": "Metformin Uptitration", "description": "Metformin uptitration, 500-1000 mg daily , add-on to Metformin 1500 mg/day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "146"}, {"groupId": "OG001", "value": "137"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "43.8"}, {"groupId": "OG001", "value": "35.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3202", "statisticalMethod": "Regression, Logistic", "paramType": "Mean Difference (Net)", "paramValue": "5.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.6", "ciUpperLimit": "17.1", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "5.79"}]}, {"type": "SECONDARY", "title": "Proportion of Patients Achieving a Therapeutic Response at Week 24 Defined as HbA1c<=6.5%", "description": "Proportion, percentage of patients in each treatment group, achieving therapeutic response, HbA1c below or equal to 6.5 percent", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-11", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "24 Weeks", "groups": [{"id": "OG000", "title": "Saxagliptin", "description": "Saxagliptin, 5 mg once daily add-on to Metformin 1500 mg/day"}, {"id": "OG001", "title": "Metformin Uptitration", "description": "Metformin uptitration, 500-1000 mg daily , add-on to Metformin 1500 mg/day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "146"}, {"groupId": "OG001", "value": "137"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20.5"}, {"groupId": "OG001", "value": "16.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6203", "statisticalMethod": "Regression, Logistic", "paramType": "Mean Difference (Net)", "paramValue": "2.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.7", "ciUpperLimit": "11.3", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.58"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 24 in Fasting Plasma Glucose", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-11", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "millimol/Liter", "timeFrame": "Baseline and 24 weeks", "groups": [{"id": "OG000", "title": "Saxagliptin", "description": "Saxagliptin, 5 mg once daily add-on to Metformin 1500 mg/day"}, {"id": "OG001", "title": "Metformin Uptitration", "description": "Metformin uptitration, 500-1000 mg daily , add-on to Metformin 1500 mg/day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "146"}, {"groupId": "OG001", "value": "137"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.07", "spread": "0.16"}, {"groupId": "OG001", "value": "-1.14", "spread": "0.17"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7627", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "0.07", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.38", "ciUpperLimit": "0.52", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.23"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 24 in Fasting Insulin", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-11", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "microUnit/milliLiter", "timeFrame": "Baseline and 24 weeks", "groups": [{"id": "OG000", "title": "Saxagliptin", "description": "Saxagliptin, 5 mg once daily add-on to Metformin 1500 mg/day"}, {"id": "OG001", "title": "Metformin Uptitration", "description": "Metformin uptitration, 500-1000 mg daily , add-on to Metformin 1500 mg/day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "146"}, {"groupId": "OG001", "value": "137"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.9", "spread": "0.82"}, {"groupId": "OG001", "value": "-2.3", "spread": "0.85"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7701", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "0.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.0", "ciUpperLimit": "2.7", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.19"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 24 in Beta-cell Function as Measured by Homeostasis Model Assessment-2-beta", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-11", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent (%)", "timeFrame": "Baseline and 24 weeks", "groups": [{"id": "OG000", "title": "Saxagliptin", "description": "Saxagliptin, 5 mg once daily add-on to Metformin 1500 mg/day"}, {"id": "OG001", "title": "Metformin Uptitration", "description": "Metformin uptitration, 500-1000 mg daily , add-on to Metformin 1500 mg/day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "146"}, {"groupId": "OG001", "value": "137"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.70", "spread": "3.01"}, {"groupId": "OG001", "value": "2.34", "spread": "3.13"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5882", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "2.39", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.22", "ciUpperLimit": "10.93", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.34"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Saxagliptin", "description": "Saxagliptin, 5 mg once daily add-on to Metformin 1500 mg/day", "seriousNumAffected": 6, "seriousNumAtRisk": 147, "otherNumAffected": 27, "otherNumAtRisk": 147}, {"id": "EG001", "title": "Metformin Uptitration", "description": "Metformin uptitration, 500-1000 mg daily , add-on to Metformin 1500 mg/day", "seriousNumAffected": 6, "seriousNumAtRisk": 139, "otherNumAffected": 22, "otherNumAtRisk": 139}], "seriousEvents": [{"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 147}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 139}]}, {"term": "Atrioventricilar Block Second Degree", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 147}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 139}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 147}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 139}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 147}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 139}]}, {"term": "Prostate Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 147}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 139}]}, {"term": "Tongue Neoplasm Malignant Stage Unspecified", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 147}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 139}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 147}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 139}]}, {"term": "Nerve Root Compression", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 147}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 139}]}, {"term": "Aortic Dissection", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 147}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 139}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 147}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 139}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 147}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 139}]}, {"term": "Obesity", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 147}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 139}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 147}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 139}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 147}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 139}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 147}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 139}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "aztrial_results_posting@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000502994", "term": "Saxagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M228152", "name": "Saxagliptin", "asFound": "Manufacturer", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}